img

Global Antidiabetic SGLT-2 Inhibitor Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Antidiabetic SGLT-2 Inhibitor Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application

Antidiabetic SGLT-2 Inhibitor report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Antidiabetic SGLT-2 Inhibitor market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Hospitals and Clinics are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Antidiabetic SGLT-2 Inhibitor industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Antidiabetic SGLT-2 Inhibitor key manufacturers include Pfizer, AstraZeneca, Johnson & Johnson, GlaxoSmithKline, Merck & Co, Eli Lilly, Sanofi, Takeda Pharmaceuticals and Novo Nordisk, etc. Pfizer, AstraZeneca, Johnson & Johnson are top 3 players and held % sales share in total in 2022.
Antidiabetic SGLT-2 Inhibitor can be divided into Canagliflozin, Empagliflozin, Dapagliflozin and Other, etc. Canagliflozin is the mainstream product in the market, accounting for % sales share globally in 2022.
Antidiabetic SGLT-2 Inhibitor is widely used in various fields, such as Hospitals, Clinics and Other,, etc. Hospitals provides greatest supports to the Antidiabetic SGLT-2 Inhibitor industry development. In 2022, global % sales of Antidiabetic SGLT-2 Inhibitor went into Hospitals filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Antidiabetic SGLT-2 Inhibitor market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report



By Company


Pfizer
AstraZeneca
Johnson & Johnson
GlaxoSmithKline
Merck & Co
Eli Lilly
Sanofi
Takeda Pharmaceuticals
Novo Nordisk
Servier Laboratories
Boehringer Ingelheim
Bristol-Myers Squibb
Segment by Type
Canagliflozin
Empagliflozin
Dapagliflozin
Other

Segment by Application


Hospitals
Clinics
Other

Segment by Region


North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Antidiabetic SGLT-2 Inhibitor market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Antidiabetic SGLT-2 Inhibitor, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Antidiabetic SGLT-2 Inhibitor industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Antidiabetic SGLT-2 Inhibitor in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Antidiabetic SGLT-2 Inhibitor introduction, etc. Antidiabetic SGLT-2 Inhibitor Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Antidiabetic SGLT-2 Inhibitor market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.

Table of Content

1 Antidiabetic SGLT-2 Inhibitor Market Overview
1.1 Antidiabetic SGLT-2 Inhibitor Product Overview
1.2 Antidiabetic SGLT-2 Inhibitor Market Segment by Type
1.2.1 Canagliflozin
1.2.2 Empagliflozin
1.2.3 Dapagliflozin
1.2.4 Other
1.3 Global Antidiabetic SGLT-2 Inhibitor Market Size by Type
1.3.1 Global Antidiabetic SGLT-2 Inhibitor Market Size Overview by Type (2018-2034)
1.3.2 Global Antidiabetic SGLT-2 Inhibitor Historic Market Size Review by Type (2018-2024)
1.3.3 Global Antidiabetic SGLT-2 Inhibitor Forecasted Market Size by Type (2024-2034)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Antidiabetic SGLT-2 Inhibitor Sales Breakdown by Type (2018-2024)
1.4.2 Europe Antidiabetic SGLT-2 Inhibitor Sales Breakdown by Type (2018-2024)
1.4.3 Asia-Pacific Antidiabetic SGLT-2 Inhibitor Sales Breakdown by Type (2018-2024)
1.4.4 Latin America Antidiabetic SGLT-2 Inhibitor Sales Breakdown by Type (2018-2024)
1.4.5 Middle East and Africa Antidiabetic SGLT-2 Inhibitor Sales Breakdown by Type (2018-2024)
2 Global Antidiabetic SGLT-2 Inhibitor Market Competition by Company
2.1 Global Top Players by Antidiabetic SGLT-2 Inhibitor Sales (2018-2024)
2.2 Global Top Players by Antidiabetic SGLT-2 Inhibitor Revenue (2018-2024)
2.3 Global Top Players by Antidiabetic SGLT-2 Inhibitor Price (2018-2024)
2.4 Global Top Manufacturers Antidiabetic SGLT-2 Inhibitor Manufacturing Base Distribution, Sales Area, Product Type
2.5 Antidiabetic SGLT-2 Inhibitor Market Competitive Situation and Trends
2.5.1 Antidiabetic SGLT-2 Inhibitor Market Concentration Rate (2018-2024)
2.5.2 Global 5 and 10 Largest Manufacturers by Antidiabetic SGLT-2 Inhibitor Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Antidiabetic SGLT-2 Inhibitor as of 2022)
2.7 Date of Key Manufacturers Enter into Antidiabetic SGLT-2 Inhibitor Market
2.8 Key Manufacturers Antidiabetic SGLT-2 Inhibitor Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Antidiabetic SGLT-2 Inhibitor Status and Outlook by Region
3.1 Global Antidiabetic SGLT-2 Inhibitor Market Size and CAGR by Region: 2018 VS 2022 VS 2034
3.2 Global Antidiabetic SGLT-2 Inhibitor Historic Market Size by Region
3.2.1 Global Antidiabetic SGLT-2 Inhibitor Sales in Volume by Region (2018-2024)
3.2.2 Global Antidiabetic SGLT-2 Inhibitor Sales in Value by Region (2018-2024)
3.2.3 Global Antidiabetic SGLT-2 Inhibitor Sales (Volume & Value) Price and Gross Margin (2018-2024)
3.3 Global Antidiabetic SGLT-2 Inhibitor Forecasted Market Size by Region
3.3.1 Global Antidiabetic SGLT-2 Inhibitor Sales in Volume by Region (2024-2034)
3.3.2 Global Antidiabetic SGLT-2 Inhibitor Sales in Value by Region (2024-2034)
3.3.3 Global Antidiabetic SGLT-2 Inhibitor Sales (Volume & Value), Price and Gross Margin (2024-2034)
4 Global Antidiabetic SGLT-2 Inhibitor by Application
4.1 Antidiabetic SGLT-2 Inhibitor Market Segment by Application
4.1.1 Hospitals
4.1.2 Clinics
4.1.3 Other
4.2 Global Antidiabetic SGLT-2 Inhibitor Market Size by Application
4.2.1 Global Antidiabetic SGLT-2 Inhibitor Market Size Overview by Application (2018-2034)
4.2.2 Global Antidiabetic SGLT-2 Inhibitor Historic Market Size Review by Application (2018-2024)
4.2.3 Global Antidiabetic SGLT-2 Inhibitor Forecasted Market Size by Application (2024-2034)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Antidiabetic SGLT-2 Inhibitor Sales Breakdown by Application (2018-2024)
4.3.2 Europe Antidiabetic SGLT-2 Inhibitor Sales Breakdown by Application (2018-2024)
4.3.3 Asia-Pacific Antidiabetic SGLT-2 Inhibitor Sales Breakdown by Application (2018-2024)
4.3.4 Latin America Antidiabetic SGLT-2 Inhibitor Sales Breakdown by Application (2018-2024)
4.3.5 Middle East and Africa Antidiabetic SGLT-2 Inhibitor Sales Breakdown by Application (2018-2024)
5 North America Antidiabetic SGLT-2 Inhibitor by Country
5.1 North America Antidiabetic SGLT-2 Inhibitor Historic Market Size by Country
5.1.1 North America Antidiabetic SGLT-2 Inhibitor Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
5.1.2 North America Antidiabetic SGLT-2 Inhibitor Sales in Volume by Country (2018-2024)
5.1.3 North America Antidiabetic SGLT-2 Inhibitor Sales in Value by Country (2018-2024)
5.2 North America Antidiabetic SGLT-2 Inhibitor Forecasted Market Size by Country
5.2.1 North America Antidiabetic SGLT-2 Inhibitor Sales in Volume by Country (2024-2034)
5.2.2 North America Antidiabetic SGLT-2 Inhibitor Sales in Value by Country (2024-2034)
6 Europe Antidiabetic SGLT-2 Inhibitor by Country
6.1 Europe Antidiabetic SGLT-2 Inhibitor Historic Market Size by Country
6.1.1 Europe Antidiabetic SGLT-2 Inhibitor Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
6.1.2 Europe Antidiabetic SGLT-2 Inhibitor Sales in Volume by Country (2018-2024)
6.1.3 Europe Antidiabetic SGLT-2 Inhibitor Sales in Value by Country (2018-2024)
6.2 Europe Antidiabetic SGLT-2 Inhibitor Forecasted Market Size by Country
6.2.1 Europe Antidiabetic SGLT-2 Inhibitor Sales in Volume by Country (2024-2034)
6.2.2 Europe Antidiabetic SGLT-2 Inhibitor Sales in Value by Country (2024-2034)
7 Asia-Pacific Antidiabetic SGLT-2 Inhibitor by Region
7.1 Asia-Pacific Antidiabetic SGLT-2 Inhibitor Historic Market Size by Region
7.1.1 Asia-Pacific Antidiabetic SGLT-2 Inhibitor Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2034
7.1.2 Asia-Pacific Antidiabetic SGLT-2 Inhibitor Sales in Volume by Region (2018-2024)
7.1.3 Asia-Pacific Antidiabetic SGLT-2 Inhibitor Sales in Value by Region (2018-2024)
7.2 Asia-Pacific Antidiabetic SGLT-2 Inhibitor Forecasted Market Size by Region
7.2.1 Asia-Pacific Antidiabetic SGLT-2 Inhibitor Sales in Volume by Region (2024-2034)
7.2.2 Asia-Pacific Antidiabetic SGLT-2 Inhibitor Sales in Value by Region (2024-2034)
8 Latin America Antidiabetic SGLT-2 Inhibitor by Country
8.1 Latin America Antidiabetic SGLT-2 Inhibitor Historic Market Size by Country
8.1.1 Latin America Antidiabetic SGLT-2 Inhibitor Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
8.1.2 Latin America Antidiabetic SGLT-2 Inhibitor Sales in Volume by Country (2018-2024)
8.1.3 Latin America Antidiabetic SGLT-2 Inhibitor Sales in Value by Country (2018-2024)
8.2 Latin America Antidiabetic SGLT-2 Inhibitor Forecasted Market Size by Country
8.2.1 Latin America Antidiabetic SGLT-2 Inhibitor Sales in Volume by Country (2024-2034)
8.2.2 Latin America Antidiabetic SGLT-2 Inhibitor Sales in Value by Country (2024-2034)
9 Middle East and Africa Antidiabetic SGLT-2 Inhibitor by Country
9.1 Middle East and Africa Antidiabetic SGLT-2 Inhibitor Historic Market Size by Country
9.1.1 Middle East and Africa Antidiabetic SGLT-2 Inhibitor Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
9.1.2 Middle East and Africa Antidiabetic SGLT-2 Inhibitor Sales in Volume by Country (2018-2024)
9.1.3 Middle East and Africa Antidiabetic SGLT-2 Inhibitor Sales in Value by Country (2018-2024)
9.2 Middle East and Africa Antidiabetic SGLT-2 Inhibitor Forecasted Market Size by Country
9.2.1 Middle East and Africa Antidiabetic SGLT-2 Inhibitor Sales in Volume by Country (2024-2034)
9.2.2 Middle East and Africa Antidiabetic SGLT-2 Inhibitor Sales in Value by Country (2024-2034)
10 Company Profiles
10.1 Pfizer
10.1.1 Pfizer Company Information
10.1.2 Pfizer Introduction and Business Overview
10.1.3 Pfizer Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2018-2024)
10.1.4 Pfizer Antidiabetic SGLT-2 Inhibitor Products Offered
10.1.5 Pfizer Recent Development
10.2 AstraZeneca
10.2.1 AstraZeneca Company Information
10.2.2 AstraZeneca Introduction and Business Overview
10.2.3 AstraZeneca Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2018-2024)
10.2.4 AstraZeneca Antidiabetic SGLT-2 Inhibitor Products Offered
10.2.5 AstraZeneca Recent Development
10.3 Johnson & Johnson
10.3.1 Johnson & Johnson Company Information
10.3.2 Johnson & Johnson Introduction and Business Overview
10.3.3 Johnson & Johnson Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2018-2024)
10.3.4 Johnson & Johnson Antidiabetic SGLT-2 Inhibitor Products Offered
10.3.5 Johnson & Johnson Recent Development
10.4 GlaxoSmithKline
10.4.1 GlaxoSmithKline Company Information
10.4.2 GlaxoSmithKline Introduction and Business Overview
10.4.3 GlaxoSmithKline Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2018-2024)
10.4.4 GlaxoSmithKline Antidiabetic SGLT-2 Inhibitor Products Offered
10.4.5 GlaxoSmithKline Recent Development
10.5 Merck & Co
10.5.1 Merck & Co Company Information
10.5.2 Merck & Co Introduction and Business Overview
10.5.3 Merck & Co Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2018-2024)
10.5.4 Merck & Co Antidiabetic SGLT-2 Inhibitor Products Offered
10.5.5 Merck & Co Recent Development
10.6 Eli Lilly
10.6.1 Eli Lilly Company Information
10.6.2 Eli Lilly Introduction and Business Overview
10.6.3 Eli Lilly Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2018-2024)
10.6.4 Eli Lilly Antidiabetic SGLT-2 Inhibitor Products Offered
10.6.5 Eli Lilly Recent Development
10.7 Sanofi
10.7.1 Sanofi Company Information
10.7.2 Sanofi Introduction and Business Overview
10.7.3 Sanofi Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2018-2024)
10.7.4 Sanofi Antidiabetic SGLT-2 Inhibitor Products Offered
10.7.5 Sanofi Recent Development
10.8 Takeda Pharmaceuticals
10.8.1 Takeda Pharmaceuticals Company Information
10.8.2 Takeda Pharmaceuticals Introduction and Business Overview
10.8.3 Takeda Pharmaceuticals Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2018-2024)
10.8.4 Takeda Pharmaceuticals Antidiabetic SGLT-2 Inhibitor Products Offered
10.8.5 Takeda Pharmaceuticals Recent Development
10.9 Novo Nordisk
10.9.1 Novo Nordisk Company Information
10.9.2 Novo Nordisk Introduction and Business Overview
10.9.3 Novo Nordisk Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2018-2024)
10.9.4 Novo Nordisk Antidiabetic SGLT-2 Inhibitor Products Offered
10.9.5 Novo Nordisk Recent Development
10.10 Servier Laboratories
10.10.1 Servier Laboratories Company Information
10.10.2 Servier Laboratories Introduction and Business Overview
10.10.3 Servier Laboratories Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2018-2024)
10.10.4 Servier Laboratories Antidiabetic SGLT-2 Inhibitor Products Offered
10.10.5 Servier Laboratories Recent Development
10.11 Boehringer Ingelheim
10.11.1 Boehringer Ingelheim Company Information
10.11.2 Boehringer Ingelheim Introduction and Business Overview
10.11.3 Boehringer Ingelheim Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2018-2024)
10.11.4 Boehringer Ingelheim Antidiabetic SGLT-2 Inhibitor Products Offered
10.11.5 Boehringer Ingelheim Recent Development
10.12 Bristol-Myers Squibb
10.12.1 Bristol-Myers Squibb Company Information
10.12.2 Bristol-Myers Squibb Introduction and Business Overview
10.12.3 Bristol-Myers Squibb Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2018-2024)
10.12.4 Bristol-Myers Squibb Antidiabetic SGLT-2 Inhibitor Products Offered
10.12.5 Bristol-Myers Squibb Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Antidiabetic SGLT-2 Inhibitor Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Antidiabetic SGLT-2 Inhibitor Industrial Chain Analysis
11.4 Antidiabetic SGLT-2 Inhibitor Market Dynamics
11.4.1 Antidiabetic SGLT-2 Inhibitor Industry Trends
11.4.2 Antidiabetic SGLT-2 Inhibitor Market Drivers
11.4.3 Antidiabetic SGLT-2 Inhibitor Market Challenges
11.4.4 Antidiabetic SGLT-2 Inhibitor Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Antidiabetic SGLT-2 Inhibitor Distributors
12.3 Antidiabetic SGLT-2 Inhibitor Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer

List of Figure

List of Tables
Table 1. Major Company of Canagliflozin
Table 2. Major Company of Empagliflozin
Table 3. Major Company of Dapagliflozin
Table 4. Major Company of Other
Table 5. Global Antidiabetic SGLT-2 Inhibitor Sales by Type 2018 VS 2022 VS 2034 (US$ Million)
Table 6. Global Antidiabetic SGLT-2 Inhibitor Sales by Type (2018-2024) & (K Pcs)
Table 7. Global Antidiabetic SGLT-2 Inhibitor Sales Market Share in Volume by Type (2018-2024)
Table 8. Global Antidiabetic SGLT-2 Inhibitor Sales by Type (2018-2024) & (US& Million)
Table 9. Global Antidiabetic SGLT-2 Inhibitor Market Share in Value by Type (2018-2024)
Table 10. Global Antidiabetic SGLT-2 Inhibitor Price by Type (2018-2024) & (USD/Pcs)
Table 11. Global Antidiabetic SGLT-2 Inhibitor Sales by Type (2024-2034) & (K Pcs)
Table 12. Global Antidiabetic SGLT-2 Inhibitor Sales Market Share in Volume by Type (2024-2034)
Table 13. Global Antidiabetic SGLT-2 Inhibitor Sales by Type (2024-2034) & (US$ Million)
Table 14. Global Antidiabetic SGLT-2 Inhibitor Sales Market Share in Value by Type (2024-2034)
Table 15. Global Antidiabetic SGLT-2 Inhibitor Price by Type (2024-2034) & (USD/Pcs)
Table 16. North America Antidiabetic SGLT-2 Inhibitor Sales by Type (2018-2024) & (K Pcs)
Table 17. North America Antidiabetic SGLT-2 Inhibitor Sales by Type (2018-2024) & (US$ Million)
Table 18. Europe Antidiabetic SGLT-2 Inhibitor Sales (K Pcs) by Type (2018-2024)
Table 19. Europe Antidiabetic SGLT-2 Inhibitor Sales by Type (2018-2024) & (US$ Million)
Table 20. Asia-Pacific Antidiabetic SGLT-2 Inhibitor Sales (K Pcs) by Type (2018-2024)
Table 21. Asia-Pacific Antidiabetic SGLT-2 Inhibitor Sales by Type (2018-2024) & (US$ Million)
Table 22. Latin America Antidiabetic SGLT-2 Inhibitor Sales (K Pcs) by Type (2018-2024)
Table 23. Latin America Antidiabetic SGLT-2 Inhibitor Sales by Type (2018-2024) & (US$ Million)
Table 24. Middle East and Africa Antidiabetic SGLT-2 Inhibitor Sales (K Pcs) by Type (2018-2024)
Table 25. Middle East and Africa Antidiabetic SGLT-2 Inhibitor Sales by Type (2018-2024) & (US$ Million)
Table 26. Global Antidiabetic SGLT-2 Inhibitor Sales by Company (2018-2024) & (K Pcs)
Table 27. Global Antidiabetic SGLT-2 Inhibitor Sales Share by Company (2018-2024)
Table 28. Global Antidiabetic SGLT-2 Inhibitor Revenue by Company (2018-2024) & (US$ Million)
Table 29. Global Antidiabetic SGLT-2 Inhibitor Revenue Share by Company (2018-2024)
Table 30. Global Market Antidiabetic SGLT-2 Inhibitor Price by Company (2018-2024) & (USD/Pcs)
Table 31. Global Antidiabetic SGLT-2 Inhibitor Top Manufacturers Manufacturing Base Distribution and Sales Area
Table 32. Global Antidiabetic SGLT-2 Inhibitor Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 33. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Antidiabetic SGLT-2 Inhibitor as of 2022)
Table 34. Date of Key Manufacturers Enter into Antidiabetic SGLT-2 Inhibitor Market
Table 35. Key Manufacturers Antidiabetic SGLT-2 Inhibitor Product Type
Table 36. Mergers & Acquisitions, Expansion Plans
Table 37. Global Antidiabetic SGLT-2 Inhibitor Market Size Comparison by Region (US$ Million): 2018 VS 2022 VS 2034
Table 38. Global Antidiabetic SGLT-2 Inhibitor Sales by Region (2018-2024) & (K Pcs)
Table 39. Global Antidiabetic SGLT-2 Inhibitor Sales Market Share in Volume by Region (2018-2024)
Table 40. Global Antidiabetic SGLT-2 Inhibitor Sales by Region (2018-2024) & (US$ Million)
Table 41. Global Antidiabetic SGLT-2 Inhibitor Sales Market Share in Value by Region (2018-2024)
Table 42. Global Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 43. Global Antidiabetic SGLT-2 Inhibitor Sales by Region (2024-2034) & (K Pcs)
Table 44. Global Antidiabetic SGLT-2 Inhibitor Sales Market Share in Volume by Region (2024-2034)
Table 45. Global Antidiabetic SGLT-2 Inhibitor Sales by Region (2024-2034) & (US$ Million)
Table 46. Global Antidiabetic SGLT-2 Inhibitor Sales Market Share in Value by Region (2024-2034)
Table 47. Global Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2024-2034)
Table 48. Global Antidiabetic SGLT-2 Inhibitor Sales by Application: 2018 VS 2022 VS 2034 (US$ Million)
Table 49. Global Antidiabetic SGLT-2 Inhibitor Sales by Application (2018-2024) & (K Pcs)
Table 50. Global Antidiabetic SGLT-2 Inhibitor Sales Market Share in Volume by Application (2018-2024)
Table 51. Global Antidiabetic SGLT-2 Inhibitor Sales by Application (2018-2024) & (US$ Million)
Table 52. Global Antidiabetic SGLT-2 Inhibitor Sales Market Share in Value by Application (2018-2024)
Table 53. Global Antidiabetic SGLT-2 Inhibitor Price by Application (2018-2024) & (USD/Pcs)
Table 54. Global Antidiabetic SGLT-2 Inhibitor Sales by Application (2024-2034) & (K Pcs)
Table 55. Global Antidiabetic SGLT-2 Inhibitor Sales Market Share in Volume by Application (2024-2034)
Table 56. Global Antidiabetic SGLT-2 Inhibitor Sales by Application (2024-2034) & (US$ Million)
Table 57. Global Antidiabetic SGLT-2 Inhibitor Sales Market Share in Value by Application (2024-2034)
Table 58. Global Antidiabetic SGLT-2 Inhibitor Price by Application (2024-2034) & (USD/Pcs)
Table 59. North America Antidiabetic SGLT-2 Inhibitor Sales by Application (2018-2024) (K Pcs)
Table 60. North America Antidiabetic SGLT-2 Inhibitor Sales by Application (2018-2024) & (US$ Million)
Table 61. Europe Antidiabetic SGLT-2 Inhibitor Sales by Application (2018-2024) (K Pcs)
Table 62. Europe Antidiabetic SGLT-2 Inhibitor Sales by Application (2018-2024) & (US$ Million)
Table 63. Asia-Pacific Antidiabetic SGLT-2 Inhibitor Sales by Application (2018-2024) (K Pcs)
Table 64. Asia-Pacific Antidiabetic SGLT-2 Inhibitor Sales by Application (2018-2024) & (US$ Million)
Table 65. Latin America Antidiabetic SGLT-2 Inhibitor Sales by Application (2018-2024) (K Pcs)
Table 66. Latin America Antidiabetic SGLT-2 Inhibitor Sales by Application (2018-2024) & (US$ Million)
Table 67. Middle East and Africa Antidiabetic SGLT-2 Inhibitor Sales by Application (2018-2024) (K Pcs)
Table 68. Middle East and Africa Antidiabetic SGLT-2 Inhibitor Sales by Application (2018-2024) & (US$ Million)
Table 69. North America Antidiabetic SGLT-2 Inhibitor Sales by Country (2018-2024) & (K Pcs)
Table 70. North America Antidiabetic SGLT-2 Inhibitor Sales Market Share in Volume by Country (2018-2024)
Table 71. North America Antidiabetic SGLT-2 Inhibitor Sales by Country (2018-2024) & (US$ Million)
Table 72. North America Antidiabetic SGLT-2 Inhibitor Sales Market Share in Value by Country (2018-2024)
Table 73. North America Antidiabetic SGLT-2 Inhibitor Sales by Country (2024-2034) & (K Pcs)
Table 74. North America Antidiabetic SGLT-2 Inhibitor Sales Market Share in Volume by Country (2024-2034)
Table 75. North America Antidiabetic SGLT-2 Inhibitor Sales by Country (2024-2034) & (US$ Million)
Table 76. North America Antidiabetic SGLT-2 Inhibitor Sales Market Share in Value by Country (2024-2034)
Table 77. Europe Antidiabetic SGLT-2 Inhibitor Sales by Country (2018-2024) & (K Pcs)
Table 78. Europe Antidiabetic SGLT-2 Inhibitor Sales Market Share in Volume by Country (2018-2024)
Table 79. Europe Antidiabetic SGLT-2 Inhibitor Sales by Country (2018-2024) & (US$ Million)
Table 80. Europe Antidiabetic SGLT-2 Inhibitor Sales Market Share in Value by Country (2018-2024)
Table 81. Europe Antidiabetic SGLT-2 Inhibitor Sales by Country (2024-2034) & (K Pcs)
Table 82. Europe Antidiabetic SGLT-2 Inhibitor Sales Market Share in Volume by Country (2024-2034)
Table 83. Europe Antidiabetic SGLT-2 Inhibitor Sales by Country (2024-2034) & (US$ Million)
Table 84. Europe Antidiabetic SGLT-2 Inhibitor Sales Market Share in Value by Country (2024-2034)
Table 85. Asia-Pacific Antidiabetic SGLT-2 Inhibitor Sales by Region (2018-2024) & (K Pcs)
Table 86. Asia-Pacific Antidiabetic SGLT-2 Inhibitor Sales Market Share in Volume by Region (2018-2024)
Table 87. Asia-Pacific Antidiabetic SGLT-2 Inhibitor Sales by Region (2018-2024) & (US$ Million)
Table 88. Asia-Pacific Antidiabetic SGLT-2 Inhibitor Sales Market Share in Value by Region (2018-2024)
Table 89. Asia-Pacific Antidiabetic SGLT-2 Inhibitor Sales by Region (2024-2034) & (K Pcs)
Table 90. Asia-Pacific Antidiabetic SGLT-2 Inhibitor Sales Market Share in Volume by Region (2024-2034)
Table 91. Asia-Pacific Antidiabetic SGLT-2 Inhibitor Sales by Region (2024-2034) & (US$ Million)
Table 92. Asia-Pacific Antidiabetic SGLT-2 Inhibitor Sales Market Share in Value by Region (2024-2034)
Table 93. Latin America Antidiabetic SGLT-2 Inhibitor Sales by Country (2018-2024) & (K Pcs)
Table 94. Latin America Antidiabetic SGLT-2 Inhibitor Sales Market Share in Volume by Country (2018-2024)
Table 95. Latin America Antidiabetic SGLT-2 Inhibitor Sales by Country (2018-2024) & (US$ Million)
Table 96. Latin America Antidiabetic SGLT-2 Inhibitor Sales Market Share in Value by Country (2018-2024)
Table 97. Latin America Antidiabetic SGLT-2 Inhibitor Sales by Country (2024-2034) & (K Pcs)
Table 98. Latin America Antidiabetic SGLT-2 Inhibitor Sales Market Share in Volume by Country (2024-2034)
Table 99. Latin America Antidiabetic SGLT-2 Inhibitor Sales by Country (2024-2034) & (US$ Million)
Table 100. Latin America Antidiabetic SGLT-2 Inhibitor Sales Market Share in Value by Country (2024-2034)
Table 101. Middle East and Africa Antidiabetic SGLT-2 Inhibitor Sales by Country (2018-2024) & (K Pcs)
Table 102. Middle East and Africa Antidiabetic SGLT-2 Inhibitor Sales Market Share in Volume by Country (2018-2024)
Table 103. Middle East and Africa Antidiabetic SGLT-2 Inhibitor Sales by Country (2018-2024) & (US$ Million)
Table 104. Middle East and Africa Antidiabetic SGLT-2 Inhibitor Sales Market Share in Value by Country (2018-2024)
Table 105. Middle East and Africa Antidiabetic SGLT-2 Inhibitor Sales by Country (2024-2034) & (K Pcs)
Table 106. Middle East and Africa Antidiabetic SGLT-2 Inhibitor Sales Market Share in Volume by Country (2024-2034)
Table 107. Middle East and Africa Antidiabetic SGLT-2 Inhibitor Sales by Country (2024-2034) & (US$ Million)
Table 108. Middle East and Africa Antidiabetic SGLT-2 Inhibitor Sales Market Share in Value by Country (2024-2034)
Table 109. Pfizer Company Information
Table 110. Pfizer Introduction and Business Overview
Table 111. Pfizer Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 112. Pfizer Antidiabetic SGLT-2 Inhibitor Product
Table 113. Pfizer Recent Development
Table 114. AstraZeneca Company Information
Table 115. AstraZeneca Introduction and Business Overview
Table 116. AstraZeneca Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 117. AstraZeneca Antidiabetic SGLT-2 Inhibitor Product
Table 118. AstraZeneca Recent Development
Table 119. Johnson & Johnson Company Information
Table 120. Johnson & Johnson Introduction and Business Overview
Table 121. Johnson & Johnson Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 122. Johnson & Johnson Antidiabetic SGLT-2 Inhibitor Product
Table 123. Johnson & Johnson Recent Development
Table 124. GlaxoSmithKline Company Information
Table 125. GlaxoSmithKline Introduction and Business Overview
Table 126. GlaxoSmithKline Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 127. GlaxoSmithKline Antidiabetic SGLT-2 Inhibitor Product
Table 128. GlaxoSmithKline Recent Development
Table 129. Merck & Co Company Information
Table 130. Merck & Co Introduction and Business Overview
Table 131. Merck & Co Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 132. Merck & Co Antidiabetic SGLT-2 Inhibitor Product
Table 133. Merck & Co Recent Development
Table 134. Eli Lilly Company Information
Table 135. Eli Lilly Introduction and Business Overview
Table 136. Eli Lilly Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 137. Eli Lilly Antidiabetic SGLT-2 Inhibitor Product
Table 138. Eli Lilly Recent Development
Table 139. Sanofi Company Information
Table 140. Sanofi Introduction and Business Overview
Table 141. Sanofi Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 142. Sanofi Antidiabetic SGLT-2 Inhibitor Product
Table 143. Sanofi Recent Development
Table 144. Takeda Pharmaceuticals Company Information
Table 145. Takeda Pharmaceuticals Introduction and Business Overview
Table 146. Takeda Pharmaceuticals Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 147. Takeda Pharmaceuticals Antidiabetic SGLT-2 Inhibitor Product
Table 148. Takeda Pharmaceuticals Recent Development
Table 149. Novo Nordisk Company Information
Table 150. Novo Nordisk Introduction and Business Overview
Table 151. Novo Nordisk Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 152. Novo Nordisk Antidiabetic SGLT-2 Inhibitor Product
Table 153. Novo Nordisk Recent Development
Table 154. Servier Laboratories Company Information
Table 155. Servier Laboratories Introduction and Business Overview
Table 156. Servier Laboratories Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 157. Servier Laboratories Antidiabetic SGLT-2 Inhibitor Product
Table 158. Servier Laboratories Recent Development
Table 159. Boehringer Ingelheim Company Information
Table 160. Boehringer Ingelheim Introduction and Business Overview
Table 161. Boehringer Ingelheim Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 162. Boehringer Ingelheim Antidiabetic SGLT-2 Inhibitor Product
Table 163. Boehringer Ingelheim Recent Development
Table 164. Bristol-Myers Squibb Company Information
Table 165. Bristol-Myers Squibb Introduction and Business Overview
Table 166. Bristol-Myers Squibb Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 167. Bristol-Myers Squibb Antidiabetic SGLT-2 Inhibitor Product
Table 168. Bristol-Myers Squibb Recent Development
Table 169. Key Raw Materials Lists
Table 170. Raw Materials Key Suppliers Lists
Table 171. Antidiabetic SGLT-2 Inhibitor Market Trends
Table 172. Antidiabetic SGLT-2 Inhibitor Market Drivers
Table 173. Antidiabetic SGLT-2 Inhibitor Market Challenges
Table 174. Antidiabetic SGLT-2 Inhibitor Market Restraints
Table 175. Antidiabetic SGLT-2 Inhibitor Distributors List
Table 176. Antidiabetic SGLT-2 Inhibitor Downstream Customers
Table 177. Research Programs/Design for This Report
Table 178. Key Data Information from Secondary Sources
Table 179. Key Data Information from Primary Sources
List of Figures
Figure 1. Antidiabetic SGLT-2 Inhibitor Product Picture
Figure 2. Global Antidiabetic SGLT-2 Inhibitor Market Size, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Antidiabetic SGLT-2 Inhibitor Market Size Status and Outlook (2018-2034) & (US$ Million)
Figure 4. Global Antidiabetic SGLT-2 Inhibitor Sales Status and Outlook (2018-2034) & (K Pcs)
Figure 5. Product Picture of Canagliflozin
Figure 6. Global Canagliflozin Sales YoY Growth (2018-2034) & (K Pcs)
Figure 7. Product Picture of Empagliflozin
Figure 8. Global Empagliflozin Sales YoY Growth (2018-2034) & (K Pcs)
Figure 9. Product Picture of Dapagliflozin
Figure 10. Global Dapagliflozin Sales YoY Growth (2018-2034) & (K Pcs)
Figure 11. Product Picture of Other
Figure 12. Global Other Sales YoY Growth (2018-2034) & (K Pcs)
Figure 13. Global Antidiabetic SGLT-2 Inhibitor Sales by Type (2018-2034) & (US$ Million)
Figure 14. Global Antidiabetic SGLT-2 Inhibitor Sales Market Share by Type in 2022 & 2034
Figure 15. North America Antidiabetic SGLT-2 Inhibitor Sales Market Share in Volume by Type in 2022
Figure 16. North America Antidiabetic SGLT-2 Inhibitor Sales Market Share in Value by Type in 2022
Figure 17. Europe Antidiabetic SGLT-2 Inhibitor Sales Market Share in Volume by Type in 2022
Figure 18. Europe Antidiabetic SGLT-2 Inhibitor Sales Market Share in Value by Type in 2022
Figure 19. Asia-Pacific Antidiabetic SGLT-2 Inhibitor Sales Market Share in Volume by Type in 2022
Figure 20. Asia-Pacific Antidiabetic SGLT-2 Inhibitor Sales Market Share in Value by Type in 2022
Figure 21. Latin America Antidiabetic SGLT-2 Inhibitor Sales Market Share in Volume by Type in 2022
Figure 22. Latin America Antidiabetic SGLT-2 Inhibitor Sales Market Share in Value by Type in 2022
Figure 23. Middle East and Africa Antidiabetic SGLT-2 Inhibitor Sales Market Share in Volume by Type in 2022
Figure 24. Middle East and Africa Antidiabetic SGLT-2 Inhibitor Sales Market Share in Value by Type in 2022
Figure 25. The 5 and 10 Largest Manufacturers in the World: Market Share by Antidiabetic SGLT-2 Inhibitor Sales in 2022
Figure 26. The 5 and 10 Largest Manufacturers in the World: Market Share by Antidiabetic SGLT-2 Inhibitor Revenue in 2022
Figure 27. Antidiabetic SGLT-2 Inhibitor Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 28. Product Picture of Hospitals
Figure 29. Global Hospitals Sales YoY Growth (2018-2034) & (K Pcs)
Figure 30. Product Picture of Clinics
Figure 31. Global Clinics Sales YoY Growth (2018-2034) & (K Pcs)
Figure 32. Product Picture of Other
Figure 33. Global Other Sales YoY Growth (2018-2034) & (K Pcs)
Figure 34. Global Antidiabetic SGLT-2 Inhibitor Sales by Application (2018-2034) & (US$ Million)
Figure 35. Global Antidiabetic SGLT-2 Inhibitor Sales Market Share by Application in 2022 & 2034
Figure 36. North America Antidiabetic SGLT-2 Inhibitor Sales Market Share in Volume by Application in 2022
Figure 37. North America Antidiabetic SGLT-2 Inhibitor Sales Market Share in Value by Application in 2022
Figure 38. Europe Antidiabetic SGLT-2 Inhibitor Sales Market Share in Volume by Application in 2022
Figure 39. Europe Antidiabetic SGLT-2 Inhibitor Sales Market Share in Value by Application in 2022
Figure 40. Asia-Pacific Antidiabetic SGLT-2 Inhibitor Sales Market Share in Volume by Application in 2022
Figure 41. Asia-Pacific Antidiabetic SGLT-2 Inhibitor Sales Market Share in Value by Application in 2022
Figure 42. Latin America Antidiabetic SGLT-2 Inhibitor Sales Market Share in Volume by Application in 2022
Figure 43. Latin America Antidiabetic SGLT-2 Inhibitor Sales Market Share in Value by Application in 2022
Figure 44. Middle East and Africa Antidiabetic SGLT-2 Inhibitor Sales Market Share in Value by Application in 2022
Figure 45. Key Raw Materials Price
Figure 46. Antidiabetic SGLT-2 Inhibitor Manufacturing Cost Structure
Figure 47. Antidiabetic SGLT-2 Inhibitor Industrial Chain Analysis
Figure 48. Channels of Distribution
Figure 49. Distributors Profiles
Figure 50. Bottom-up and Top-down Approaches for This Report
Figure 51. Data Triangulation
Figure 52. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries